<p>新英格兰资产管理公司在最近向证券交易委员会（SEC）提交的文件中表示，在第一季度将其在强生（NYSE:JNJ - 免费报告）的持股比例提高了 13.0%。该基金在此期间额外购买了 7,325 股后，持有该公司 63,464 股股票。强生约占新英格兰资产管理公司投资组合的 1.7%，是其第十大持仓。新英格兰资产管理公司在强生的持股在最近的报告期末价值为 10,525,000 美元。</p>
<ul>
<li>随着市场轮动，这只医疗 ETF 引领潮流</li>
</ul>
<p>其他一些机构投资者和对冲基金最近也调整了对该公司的持股。Brighton Jones LLC 在第四季度将其在强生的股份提高了 13.9%。Brighton Jones LLC 现在持有 51,876 股该公司的股票，价值 7,502,000 美元，此前在此期间又购买了 6,332 股。Hudson Value Partners LLC 在第四季度将其在强生的股份提高了 2.5%。Hudson Value Partners LLC 现在持有 41,403 股该公司的股票，价值 5,648,000 美元，此前在此期间又购买了 1,022 股。Corton Capital Inc.在第四季度购买了强生的新股份，价值约为 205,000 美元。CoreCap Advisors LLC 在第四季度将其在强生的股份提高了 8.1%。CoreCap Advisors LLC 现在持有 17,667 股该公司的股票，价值 2,555,000 美元，此前在上个季度又购买了 1,318 股。最后，Citizens Business Bank 在第四季度将其在强生的股份提高了 52.7%。Citizens Business Bank 现在持有 5,297 股该公司的股票，价值 766,000 美元，此前在上个季度又购买了 1,828 股。目前 69.55% 的股票由对冲基金和其他机构投资者持有。</p>
<p>获取 <strong>强生</strong> 的提醒：</p>
<h2>强生股票上涨 0.4%</h2>
<p>强生股票在周五开盘价为 178.64 美元。强生的 12 个月低点为 140.68 美元，12 个月高点为 181.16 美元。该公司的流动比率为 1.01，速动比率为 0.76，债务与股本比率为 0.50。该股票的 50 日移动平均价格为 168.06 美元，200 日移动平均价格为 160.60 美元。该股票的市值为 4302.3 亿美元，市盈率为 19.11，市盈增长比率为 2.27，贝塔值为 0.40。</p>
<ul>
<li>JNJ 股票的上涨信号显示对新增长路径的信心</li>
</ul>
<p>强生（NYSE:JNJ - 获取免费报告）最近一次发布财报是在 7 月 16 日，周三。该公司报告每股收益（EPS）为 2.77 美元，超出市场共识预期的 2.68 美元，超出 0.09 美元。强生的股本回报率为 32.49%，净利润率为 25.00%。该公司在本季度的收入为 237.4 亿美元，而分析师预期为 228.5 亿美元。在去年同期，该公司每股收益为 2.82 美元。与去年同期相比，该公司的收入增长了 5.8%。强生已将其 2025 财年的指导目标设定为每股收益 10.800-10.900 美元。股票研究分析师预测强生在当前财年将发布每股收益 10.58 美元。</p>
<h2>强生宣布分红</h2>
<p>该公司最近还披露了季度分红，将于 9 月 9 日（星期二）支付。8 月 26 日（星期二）的股东将获得每股 1.30 美元的分红。这相当于每年 5.20 美元的分红，收益率为 2.9%。该分红的除息日为 8 月 26 日（星期二）。强生的派息比率目前为 55.61%。</p>
<h2>分析师评级变动</h2>
<ul>
<li>3 只大分红股票，强劲收益支撑它们</li>
</ul>
<p>几位股票分析师最近对 JNJ 股票发表了评论。Piper Sandler 在 7 月 17 日（星期四）的研究报告中重申了对强生股票的 “增持” 评级。华尔街 Zen 在 7 月 18 日（星期五）的研究报告中将强生的评级从 “强力买入” 下调至 “买入”。瑞银集团在 7 月 17 日（星期四）的研究报告中将强生的目标价从 180.00 美元提高至 190.00 美元，并给予该公司 “买入” 评级。Erste Group Bank 在 7 月 23 日（星期三）的研究报告中将强生的评级从 “持有” 上调至 “买入”。最后，Guggenheim 在 7 月 17 日（星期四）的研究报告中重申了 “中性” 评级，并将强生的目标价设定为 167.00 美元（上调自 164.00 美元）。两位股票研究分析师对该股票给予了 “强力买入” 评级，九位给予了 “买入” 评级，九位对该公司的股票给予了 “持有” 评级。根据 MarketBeat.com 的数据，强生目前的共识评级为 “适度买入”，共识目标价为 176.29 美元。</p>
<p><strong>查看我们对 JNJ 的最新分析</strong></p>
<h2>强生公司简介</h2>
<p>（免费报告）</p>
<p>强生是一家控股公司，专注于医疗领域产品的研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过强生</li>
<li>想在下跌趋势中获利？下跌趋势的解释。</li>
<li>这里是 Oklo 与其他核创业公司的区别</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投资股票</li>
<li>为什么 Marvell 的 19% 下跌可能是一个很好的买入机会</li>
<li>房地产投资信托是否值得在你的投资组合中占有一席之地？</li>
<li>Daqo New Energy：太阳能垄断者推出 1 亿美元的回购计划</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在强生吗？</h2>
<p>在考虑强生之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
<p>虽然强生目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>新英格兰资产管理公司在第一季度将其在强生（NYSE: JNJ）的持股增加了 13.0%，目前持有 63,464 股，价值 1050 万美元。其他机构投资者也增加了他们的持股。JNJ 股票开盘价为 178.64 美元，12 个月的价格区间为 140.68 美元至 181.16 美元。公司报告第二季度每股收益为 2.77 美元，超出预期，并将 2025 财年的指导目标设定为每股收益 10.800-10.900 美元。每股 1.30 美元的季度股息将于 9 月 9 日支付。分析师的评级意见不一，有的上调评级，有的下调评级</p>

<p>New England Asset Management Inc. lifted its position in Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 13.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 63,464 shares of the company's stock after buying an additional 7,325 shares during the period. Johnson &amp; Johnson makes up about 1.7% of New England Asset Management Inc.'s investment portfolio, making the stock its 10th biggest position. New England Asset Management Inc.'s holdings in Johnson &amp; Johnson were worth $10,525,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>新英格兰资产管理公司在最近向证券交易委员会（SEC）提交的文件中表示，在第一季度将其在强生（NYSE:JNJ - 免费报告）的持股比例提高了 13.0%。该基金在此期间额外购买了 7,325 股后，持有该公司 63,464 股股票。强生约占新英格兰资产管理公司投资组合的 1.7%，是其第十大持仓。新英格兰资产管理公司在强生的持股在最近的报告期末价值为 10,525,000 美元。</p>
</div><ul>
<li>As the Market Rotates, This Healthcare ETF Is Leading the Way</li>
</ul>
<div class="lb-trans"><ul>
<li>随着市场轮动，这只医疗 ETF 引领潮流</li>
</ul>
</div><p>A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Brighton Jones LLC raised its stake in Johnson &amp; Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after acquiring an additional 6,332 shares during the period. Hudson Value Partners LLC raised its stake in Johnson &amp; Johnson by 2.5% during the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after acquiring an additional 1,022 shares during the period. Corton Capital Inc. bought a new stake in Johnson &amp; Johnson during the 4th quarter worth approximately $205,000. CoreCap Advisors LLC lifted its position in shares of Johnson &amp; Johnson by 8.1% in the fourth quarter. CoreCap Advisors LLC now owns 17,667 shares of the company's stock valued at $2,555,000 after acquiring an additional 1,318 shares in the last quarter. Finally, Citizens Business Bank lifted its position in shares of Johnson &amp; Johnson by 52.7% in the fourth quarter. Citizens Business Bank now owns 5,297 shares of the company's stock valued at $766,000 after acquiring an additional 1,828 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金最近也调整了对该公司的持股。Brighton Jones LLC 在第四季度将其在强生的股份提高了 13.9%。Brighton Jones LLC 现在持有 51,876 股该公司的股票，价值 7,502,000 美元，此前在此期间又购买了 6,332 股。Hudson Value Partners LLC 在第四季度将其在强生的股份提高了 2.5%。Hudson Value Partners LLC 现在持有 41,403 股该公司的股票，价值 5,648,000 美元，此前在此期间又购买了 1,022 股。Corton Capital Inc.在第四季度购买了强生的新股份，价值约为 205,000 美元。CoreCap Advisors LLC 在第四季度将其在强生的股份提高了 8.1%。CoreCap Advisors LLC 现在持有 17,667 股该公司的股票，价值 2,555,000 美元，此前在上个季度又购买了 1,318 股。最后，Citizens Business Bank 在第四季度将其在强生的股份提高了 52.7%。Citizens Business Bank 现在持有 5,297 股该公司的股票，价值 766,000 美元，此前在上个季度又购买了 1,828 股。目前 69.55% 的股票由对冲基金和其他机构投资者持有。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生</strong> 的提醒：</p>
</div><h2>Johnson &amp; Johnson Trading Up 0.4%</h2>
<div class="lb-trans"><h2>强生股票上涨 0.4%</h2>
</div><p>Shares of JNJ stock opened at $178.64 on Friday. Johnson &amp; Johnson has a 12-month low of $140.68 and a 12-month high of $181.16. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock's 50-day moving average price is $168.06 and its 200-day moving average price is $160.60. The stock has a market capitalization of $430.23 billion, a price-to-earnings ratio of 19.11, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40.</p>
<div class="lb-trans"><p>强生股票在周五开盘价为 178.64 美元。强生的 12 个月低点为 140.68 美元，12 个月高点为 181.16 美元。该公司的流动比率为 1.01，速动比率为 0.76，债务与股本比率为 0.50。该股票的 50 日移动平均价格为 168.06 美元，200 日移动平均价格为 160.60 美元。该股票的市值为 4302.3 亿美元，市盈率为 19.11，市盈增长比率为 2.27，贝塔值为 0.40。</p>
</div><ul>
<li>JNJ Stock Surge Signals Confidence in New Growth Path</li>
</ul>
<div class="lb-trans"><ul>
<li>JNJ 股票的上涨信号显示对新增长路径的信心</li>
</ul>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson &amp; Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the previous year, the firm posted $2.82 earnings per share. The business's revenue was up 5.8% compared to the same quarter last year. Johnson &amp; Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts predict that Johnson &amp; Johnson will post 10.58 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ - 获取免费报告）最近一次发布财报是在 7 月 16 日，周三。该公司报告每股收益（EPS）为 2.77 美元，超出市场共识预期的 2.68 美元，超出 0.09 美元。强生的股本回报率为 32.49%，净利润率为 25.00%。该公司在本季度的收入为 237.4 亿美元，而分析师预期为 228.5 亿美元。在去年同期，该公司每股收益为 2.82 美元。与去年同期相比，该公司的收入增长了 5.8%。强生已将其 2025 财年的指导目标设定为每股收益 10.800-10.900 美元。股票研究分析师预测强生在当前财年将发布每股收益 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Announces Dividend</h2>
<div class="lb-trans"><h2>强生宣布分红</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson &amp; Johnson's payout ratio is presently 55.61%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，将于 9 月 9 日（星期二）支付。8 月 26 日（星期二）的股东将获得每股 1.30 美元的分红。这相当于每年 5.20 美元的分红，收益率为 2.9%。该分红的除息日为 8 月 26 日（星期二）。强生的派息比率目前为 55.61%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>3 Big Dividend Plays With Strong Earnings to Back Them</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只大分红股票，强劲收益支撑它们</li>
</ul>
</div><p>Several equities analysts have recently commented on JNJ shares. Piper Sandler restated an &#34;overweight&#34; rating on shares of Johnson &amp; Johnson in a research report on Thursday, July 17th. Wall Street Zen downgraded Johnson &amp; Johnson from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Friday, July 18th. UBS Group boosted their price objective on Johnson &amp; Johnson from $180.00 to $190.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, July 17th. Erste Group Bank upgraded Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Wednesday, July 23rd. Finally, Guggenheim restated a &#34;neutral&#34; rating and issued a $167.00 price objective (up from $164.00) on shares of Johnson &amp; Johnson in a research report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Johnson &amp; Johnson currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $176.29.</p>
<div class="lb-trans"><p>几位股票分析师最近对 JNJ 股票发表了评论。Piper Sandler 在 7 月 17 日（星期四）的研究报告中重申了对强生股票的 “增持” 评级。华尔街 Zen 在 7 月 18 日（星期五）的研究报告中将强生的评级从 “强力买入” 下调至 “买入”。瑞银集团在 7 月 17 日（星期四）的研究报告中将强生的目标价从 180.00 美元提高至 190.00 美元，并给予该公司 “买入” 评级。Erste Group Bank 在 7 月 23 日（星期三）的研究报告中将强生的评级从 “持有” 上调至 “买入”。最后，Guggenheim 在 7 月 17 日（星期四）的研究报告中重申了 “中性” 评级，并将强生的目标价设定为 167.00 美元（上调自 164.00 美元）。两位股票研究分析师对该股票给予了 “强力买入” 评级，九位给予了 “买入” 评级，九位对该公司的股票给予了 “持有” 评级。根据 MarketBeat.com 的数据，强生目前的共识评级为 “适度买入”，共识目标价为 176.29 美元。</p>
</div><p><strong>View Our Latest Analysis on JNJ</strong></p>
<div class="lb-trans"><p><strong>查看我们对 JNJ 的最新分析</strong></p>
</div><h2>Johnson &amp; Johnson Profile</h2>
<div class="lb-trans"><h2>强生公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>强生是一家控股公司，专注于医疗领域产品的研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>Want to Profit on the Downtrend? Downtrends, Explained.</li>
<li>Here's What Separates Oklo From the Rest of the Nuclear Startups</li>
<li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li>
<li>Why Marvell’s 19% Drop Could Be a Big Buy-the-Dip Opportunity</li>
<li>Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?</li>
<li>Daqo New Energy: Solar Monopoly Launches $100M Buyback</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过强生</li>
<li>想在下跌趋势中获利？下跌趋势的解释。</li>
<li>这里是 Oklo 与其他核创业公司的区别</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投资股票</li>
<li>为什么 Marvell 的 19% 下跌可能是一个很好的买入机会</li>
<li>房地产投资信托是否值得在你的投资组合中占有一席之地？</li>
<li>Daqo New Energy：太阳能垄断者推出 1 亿美元的回购计划</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在强生吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑强生之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然强生目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

新英格兰资产管理公司增持了强生 $JNJ 的股份